Request a copy

Full Text

• Scott DW, Miller WH, Griffin CE., Skin immune system and allergic skin diseases. In: Scott DW, Miller WH, Griffin CE, (eds). Muller and Kirk’s small animal dermatology. 6th ed. Philadelphia, PA: WB Saunders, 2001, pp 543–666.
• Favrot C, Steffan J, Seewald W,. Establishment of diagnostic criteria for feline nonflea-induced hypersensitivity dermatitis. Vet Dermatol 2012; 23: 45–50.
• Wisselink MA, Willemse T., The efficacy of cyclosporine A in cats with presumed atopic dermatitis: a double blind, randomised prednisolone-controlled study. Vet J 2009; 180: 55–59.
• Ortalda C, Noli C, Colombo S,. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats. Vet Dermatol 2015; 26: 235–e52.
• Scarampella F, Abramo F, Noli C., Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet Dermatol 2001; 2: 29–39.
• Wildermuth K, Zabel S, Rosychuk RA., The efficacy of cetirizine hydrochloride on the pruritus of cats with atopic dermatitis: a randomized, double-blind, placebo-controlled, crossover study. Vet Dermatol 2013; 24: 576–581.
• Park HJ, Park JS, Hayek MG,. Dietary fish oil and flaxseed oil suppress inflammation and immunity in cats. Vet Immunol Immunopathol 2011; 141: 301–306.
• Ravens PA, Xu BJ, Vogelnest LJ., Feline atopic dermatitis: a retrospective study of 45 cases (2001–2012). Vet Dermatol 2014; 25: 95–102.
• Sedlacek HS, Ramsey DS, Boucher JF,. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. J Vet Pharmacol Ther 2008; 31: 533–537.
• He A, Alhariri JM, Sweren RJ,. Aprepitant for the treatment of chronic refractory pruritus. Biomed Res Int 2017; 2017. DOI: 10.1155/2017/4790810.
• Serrano L, Martinez-Escala ME, Zhou XA,. Pruritus in cutaneous T-cell lymphoma and its management. Dermatol Clin 2018; 36: 245–258.
• Hagermark O, Hokfelt T, Pernow B., Flare and itch induced by substance P in human skin. J Invest Dermatol 1978; 71: 233–235.
• Hill PB, Lau P, Rybnicek J., Development of an owner-assessed scale to measure the severity of pruritus in dogs. Vet Dermatol 2007; 18: 301–308.
• Steffan J, Olivry T, Forster SL,. Responsiveness and validity of the SCORFAD, an extent and severity scale for feline hypersensitivity dermatitis. Vet Dermatol 2012; 23: 410–417.
• Diesel AB., Symptomatic treatments. In: Noli C, Foster A, Rosenkrantz W, (eds). Veterinary allergy. Oxford: Wiley Blackwell, 2014, pp 228–233.
• Wisselink MA, Willemse T., The efficacy of cyclosporine A in cats with presumed atopic dermatitis: a double blind, randomised prednisolone-controlled study. Vet J 2009; 180: 55–59.
• King S, Favrot C, Messinger L,. A randomized doubleblinded placebo controlled study to evaluate an effective ciclosporin dose for treatment of feline hypersensitivity dermatitis. Vet Dermatol 2012; 23: 440–447.
• Järvikallio A, Harvima IT, Naukkarinen A., Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res 2003; 295: 2–7.
• Abadìa Molina F, Burrows NP, Jones RR,. Increased sensory neuropeptides in nodular prurigo: a quantitative immunohistochemical analysis. Br J Dermatol 1992; 127: 344–351.
• Haas S, Capellino S, Phan NQ,. Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. J Dermatol Sci 2010; 58: 193–197.
• Fjellner B, Hagermark O., Studies on pruritogenic and histamine-releasing effects of some putative peptide neurotransmitters. Acta Derm Venereol 1981; 61: 245–250.
• Jorizzo JL, Coutts AA, Eady RA,. Vascular responses of human skin to injection of substance P and mechanism of action. Eur J Pharmacol 1983; 87: 67–76.
• Salomon J, Baran E., The role of selected neuropeptides in pathogenesis of atopic dermatitis. J Eur Acad Dermatol Venereol 2008; 22: 223–228.
• Mollanazar NK, Smith PK, Yosipovitch G., Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol 2016; 51: 263–292.
• Kubanov AA, Katunina OR, Chikin VV., Expression of neuropeptides, neurotrophins, and neurotransmitters in the skin of patients with atopic dermatitis and psoriasis. Bull Exp Biol Med 2015; 159: 318–322.
• Marsella R, Nicklin CF, Melloy C., The effects of capsaicin topical therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over clinical trial. Vet Dermatol 2002; 13: 131–139.
• Grobman M, Krumme S, Outi H,. Acute neurokinin-1 receptor antagonism fails to dampen airflow limitation or airway eosinophilia in an experimental model of feline asthma. J Feline Med Surg 2016; 18: 176–181.
• Grobman M, Graham A, Outi H,. Chronic neurokinin-1 receptor antagonism fails to ameliorate clinical signs, airway hyper-responsiveness or airway eosinophilia in an experimental model of feline asthma. J Feline Med Surg 2016; 18: 273–279.
• O’Connor TM, O’Connell J, O’Brien DI,. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201: 167–180.
• Ständer S, Luger TA., NK-1 antagonists and itch. Handb Exp Pharmacol 2015; 226: 237–255.
• Ohmura T, Hayashi T, Satoh Y,. Involvement of substance P in scratching behaviour in an atopic dermatitis model. Eur J Pharmacol 2004; 491: 191–194.
• Quimby JM, Brock WT, Moses K,. Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded, placebo-controlled clinical trial. J Feline Med Surg 2015; 17: 692–697.
• Hickman MA, Cox SR, Mahabir S,. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 2008; 31: 220–229.
• Koch SN, Torres SMF, Diaz S,. Subcutaneous administration of ciclosporin in 11 allergic cats – a pilot open-label uncontrolled clinical trial. Vet Dermatol 2018; 29: 107–e43.